FDA Accepts Supplement for STEGLATRO (Ertugliflozin) by Merck
The FDA has accepted a supplemental application for STEGLATRO (ertugliflozin) from Merck.
Asset / Drug
Drug and asset intelligence for STEGLATRO with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.